Advanced Search
Contact | Corporate | Help

Ranibizumab (Lucentis) for Polypoidal Choroidal Vasculopathy

Sponsors:
  • Southeast Retina Center, Georgia
  • Genentech
Phases:
  • Phase I
  • Phase II
IndicationsAcronym:
  • Polypoidal Choroidal Vasculopathy (PCV)
Age Groups:
  • Adult
  • Senior
Gender:
Both
Names:
  • Drug: ranibizumab 0.5 or 0.3 mg/0.05 cc
Enrollment:
50

Additional information about NCT00837330.


SourceSolution © 2008-2012